Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Mexico Health Reporter.
Press releases published on October 23, 2025
Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third quarter 2025 financial results after market …
Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Mir Imran Each of Samsara and Anomaly has the right to designate one …
Leukemia Survivor Introduced to Lifesaving Donor by Former NFL Player at Boston College Donor Drive
BOCA RATON, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- A Boston College student body was witness to a profoundly emotional moment this week as a leukemia survivor met the stranger who saved his life through a stem cell donation facilitated by the Gift of Life …
Carrington College in Albuquerque Invites Community to Explore Healthcare Careers at Nursing Open House
ALBUQUERQUE, N.M., Oct. 23, 2025 (GLOBE NEWSWIRE) -- The Carrington College campus in Albuquerque will host a Nursing Open House on Thursday, Nov. 6, from 10:30 a.m. to 7 p.m., inviting prospective students and community members to explore its healthcare …
New Clinical Data Confirms Yomi® Robotic System Enhances Efficiency in Dental Implant Surgery
MIAMI, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Neocis®, the leader in robotic-assisted dental surgery, today announced new clinical data highlighting the significant efficiency benefits of its Yomi® Robotic System, the first and only FDA-cleared robotic platform …
Award-Winning Film An Inconvenient Study Sparks Global Debate on Vaccine Safety and Chronic Disease
AUSTIN, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The award-winning film An Inconvenient Study has been seen by millions following its global premiere on October 12th, sparking international discussion and debate about vaccine safety, scientific …
Progyny, Inc. Announces Details for Its Third Quarter 2025 Results Report
NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended September 30, 2025 after the close of the market on …
Europe Approves New Alzheimer’s Treatment -- Why is the U.S. Still Waiting?
Farmington Hills, Michigan, Oct. 23, 2025 (GLOBE NEWSWIRE) -- “We made every effort to bring this treatment to U.S. patients first,” said Cerezen Founder and CEO Manoj Bhargava. “However, it seems politics is more important than people’s lives. The current …
Hidradenitis Suppurativa Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 24+ Companies and 26+ Therapies | DelveInsight
New York, USA, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Hidradenitis Suppurativa Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 24+ Companies and 26+ Therapies | DelveInsight The hidradenitis suppurativa market is poised for strong growth, …
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer 64% overall response rate in gynecological cancers …
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors -Robust body of preclinical data supports ALX2004 differentiation in EGFR-ADC class …
eteraflex connects and CliniExperts Announce Global Alliance to Redefine Clinical Research and Regulatory Services Delivery
Princeton, NJ, Oct. 23, 2025 (GLOBE NEWSWIRE) -- eteraflex connects and CliniExperts have announced a strategic partnership that unites their complementary expertise in clinical research, regulatory strategy, and technology integration under a single, …
Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmation of all financial targets for 2025.
Revenue at September 30, 2025 Return to growth in Q3 2025 9-month revenue: €586.5 million, down 2.8% at CER1 and on a like-for-like basis2, largely due to the fall in activity in France An increase in Q3 of 2.6% at CER and on a like-for-like basis, …
Guerbet : Chiffre d’affaires au 30 septembre 2025. Retour de la croissance au 3ème trimestre 2025. Confirmation de l’ensemble des objectifs financiers 2025.
Chiffre d’affaires au 30 septembre 2025 Retour de la croissance au 3ème trimestre 2025 Chiffre d’affaires à 9 mois : 586,5 M€, en retrait de 2,8% à TCC1 et périmètre comparable2, largement dû à la baisse de l’activité en France Au troisième …
Rentschler Biopharma Inc. named Manufacturer of the Year for Central Massachusetts
Company honored by state’s Legislative Manufacturing Caucus for outstanding leadership and contributions to the manufacturing sector State-of-the-art production line is bringing in new clients, new projects, new indications LAUPHEIM, Germany and MILFORD, …
Roxanna Gapstur, Ph.D., R.N., WellSpan president and CEO, named a Distinguished Daughter of PA
York, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- WellSpan Health president and CEO Roxanna Gapstur, Ph.D., R.N., has been named one of nine women inductees as a Distinguished Daughter of Pennsylvania for 2025. Gapstur was recognized recently at an event …
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per plan LAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, …
BeautyHealth to Report Third Quarter 2025 Financial Results on November 6, 2025
LONG BEACH, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced it will report third quarter 2025 financial results after market close on Thursday, November 6, 2025. The …
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence …